Related references
Note: Only part of the references are listed.Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase
Hagop M. Kantarjian et al.
CANCER (2009)
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephanie Dulucq et al.
BLOOD (2008)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
N. Widmer et al.
BRITISH JOURNAL OF CANCER (2008)
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
L. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations
S. Pursche et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Use of therapeutic drug monitoring in CML patients on imatinib - Response
Francois-Xavier Mahon et al.
BLOOD (2007)
Therapeutic drug monitoring in CML patients on imatinib
Carolyn Blasdel et al.
BLOOD (2007)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome
JH Beumer et al.
PHARMACOTHERAPY (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Karine Titier et al.
THERAPEUTIC DRUG MONITORING (2005)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
AL Dewar et al.
BLOOD (2005)
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients
P Breedveld et al.
CANCER RESEARCH (2005)
Clinical pharmacokinetics of imatinib
B Peng et al.
CLINICAL PHARMACOKINETICS (2005)
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
H Kantarjian et al.
BLOOD (2004)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
AE Bolton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effect of St John's wort on imatinib mesylate pharmacokinetics
RF Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
C Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
CD Mol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
H Burger et al.
BLOOD (2004)
The influence of St. John's Wort on the pharmacokinetics and protein binding of imatinib mesylate
P Smith
PHARMACOTHERAPY (2004)
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
C Özvegy-Laczka et al.
MOLECULAR PHARMACOLOGY (2004)
Imatinib therapy in chronic myeloid leukemia
LC Crossman et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia
SG O'Brien et al.
BRITISH JOURNAL OF CANCER (2003)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux
HQ Dai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
HM Kantarjian et al.
BLOOD (2003)
Interaction of imatinib mesilate with human P-glycoprotein
A Hamada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
T Hegedüs et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry
R Bakhtiar et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2002)
Multifaceted approach to the treatment of Bcr-Abl-positive leukemias
M O'Dwyer
ONCOLOGIST (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
C Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
